Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PEPD | P12955 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12604939 | 1.00 | HSD17B10 (0.36) | HSD17B10PEPDHDAC8LMNANPSR1 | |
| SCHEMBL16800203 | 0.94 | PEPD (0.40) | HSD17B10PEPDHDAC8LMNANPSR1 | |
| SCHEMBL15660593 | 0.92 | PEPD (0.44) | HSD17B10PEPDHDAC8LMNANPSR1 | |
| SCHEMBL30987654 | 0.92 | PEPD (0.44) | HSD17B10PEPDHDAC8LMNANPSR1 | |
| SCHEMBL15660596 | 0.92 | PEPD (0.44) | HSD17B10PEPDHDAC8LMNANPSR1 | |
| SCHEMBL10138527 | 0.88 | HSD17B10 (0.42) | HSD17B10HDAC8LMNANPSR1SMN1; SMN2 | |
| SCHEMBL12604940 | 0.88 | HSD17B10 (0.42) | HSD17B10HDAC8LMNANPSR1SMN1; SMN2 | |
| SCHEMBL29524116 | 0.88 | FKBP1A (0.38) | HSD17B10PEPDHDAC8LMNANPSR1 | |
| SCHEMBL23824537 | 0.87 | HSD17B10 (0.41) | HSD17B10HDAC8LMNANPSR1SMN1; SMN2 | |
| SCHEMBL24113141 | 0.87 | HSD17B10 (0.41) | HSD17B10HDAC8LMNANPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| CN-114585637-B | MASP-inhibitory compounds and uses thereof | 拜耳公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| CN-114585637-A | MASP inhibiting compounds and uses thereof | 拜耳公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3966226-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| WO-2020225095-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-12 | — | — | WO | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | HSD17B10 3996/4885PEPD 32/4885HDAC8 3189/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | HSD17B10 3996/4885PEPD 32/4885HDAC8 3189/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | HSD17B10 3996/4885PEPD 32/4885HDAC8 3189/4885 |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | HSD17B10 3996/4885PEPD 32/4885HDAC8 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.